| Symbol | TELO |
|---|---|
| Name | TELOMIR PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 SE 2ND ST,SUITE 2000,#1009, MIAMI, Florida, 33131, United States |
| Telephone | +1 786 - 396-6723 |
| Fax | — |
| — | |
| Website | https://www.telomirpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001971532 |
| Description | Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Telomir Pharmaceuticals, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097283 <b>Size:</b> 7 KB
Read more(99% Neutral) TELOMIR PHARMACEUTICALS, INC. (TELO) Provides Update on overexpressed for aggressive cancers
Read moreTelomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
Read moreNew Form DEF 14A - Telomir Pharmaceuticals, Inc. <b>Filed:</b> 2026-07-28 <b>AccNo:</b> 0001493152-26-035026 <b>Size:</b> 1 MB
Read moreDirector Whalen Matthew Pratt 🟢 acquired 50.0K shares (1 derivative) of Telomir Pharmaceuticals, Inc. (TELO) at $1.34 Transaction Date: Apr 16, 2026 | Filing ID: 034813
Read moreDirector MacPherson Edward Clouston 🟢 acquired 50.0K shares (1 derivative) of Telomir Pharmaceuticals, Inc. (TELO) at $1.34 Transaction Date: Apr 16, 2026 | Filing ID: 034811
Read moreDirector Del Giudice Matthew Paul 🟢 acquired 50.0K shares (1 derivative) of Telomir Pharmaceuticals, Inc. (TELO) at $1.34 Transaction Date: Apr 16, 2026 | Filing ID: 034812
Read more(75% Positive) TELOMIR PHARMACEUTICALS, INC. (TELO) Provides Update on online for a Diet-Induced Zebrafish Model of Type 2 Diabetes
Read moreNew Form 3 - Telomir Pharmaceuticals, Inc. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001493152-26-027958 <b>Size:</b> 3 KB
Read more(99% Neutral) TELOMIR PHARMACEUTICALS, INC. (TELO) Announces New Board Appointment
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Nega… | Phase1 | Triple-Negative Breast Cancer (TNBC) | Not_Yet_Recruiting | 2026-10-01 | 2027-11-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Zn-Telomir | Other | Phase PHASE1 | Triple-Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07581314 |
| Zn-Telomir | Other | Phase PHASE1 | Triple-Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07581314 |
| Zn-Telomir | Other | Phase PHASE1 | Triple-Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07581314 |
| Zn-Telomir | Other | Phase PHASE1 | Triple-Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07581314 |
| Zn-Telomir | Other | Phase PHASE1 | Triple-Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07581314 |
| Zn-Telomir | Other | Phase PHASE1 | Triple-Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07581314 |
| Zn-Telomir | Other | Phase PHASE1 | Triple-Negative Breast Cancer (TNBC) | NOT_YET_RECRUITING | NCT07581314 |